The Swiss life sciences industry, despite a challenging dip in job vacancies in 2023 (down by 31.4%), shows a robust rebound in 2024, with vacancies projected to rise by 24.1%. R&D roles have been notably active, reflecting global trends and a renewed push in innovation.
The UK pharmaceuticals sector is recovering from its post-pandemic slowdown, with a focus on addressing the backlog of drug approvals by the MHRA. As approvals accelerate, pharmaceutical manufacturing is ramping up, contributing to an 8.8% increase in engineering vacancies in 2024 compared to last year.
The 2023 year saw a dip across both DACH and BENELUX regions, reflected by the EU data. DACH has kept higher numbers than BENELUX since the start of 2022, but this gap is now shortening whilst still being apparent. So far, the first half 2024 is projected to see lower volumes than the full-year estimate.
The UK’s political landscape is particularly noteworthy with Europe facing a series of summer elections. If it gains power, the Labour Party has explicitly stated its intention to improve trade relations with the EU. Although specific plans have not been detailed, any shift in this direction could alleviate the sectoral dampening caused by Brexit.
As the UK moves past the pandemic, the life sciences industry is still adjusting to the challenges associated with the post-Brexit regime. This, combined with the slowdown in trials during the pandemic, has resulted in a slowdown in recruitment within the sector, particularly affecting regulatory affairs professionals.
With the slump in the pharmaceutical sector set to continue, the long-awaited reforms to the MHRA have yet to materialise. As a result, drug approval in the UK lags behind the EU, further depressing the sector. 2023 seems to be the low point in that there has been an uptick in Q1 so far, and if this continues, it will increase by 9.1% this year compared to last. The recovery has been in London specifically, with volumes up 26.1% on last year.
